Get the Stockscreener App
0.9452
0.54%
0.0051
After Hours:
.94
-0.0052
-0.55%
Aprea Therapeutics Inc stock is traded at $0.9452, with a volume of 80,460.
It is up +0.54% in the last 24 hours and up +1.89% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$0.9401
Open:
$0.98
24h Volume:
80,460
Relative Volume:
0.84
Market Cap:
$6.61M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.2369
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
+10.81%
1M Performance:
+1.89%
6M Performance:
-49.72%
1Y Performance:
-76.01%
1-Day Range:
$0.94
$1.00
1-Week Range:
$0.84
$1.00
52-Week Range:
$0.84
$4.65
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.9452 | 6.57M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
MSN Money - MSN
Aprea Therapeutics, Inc. Updates Corporate Presentation - TradingView — Track All Markets
Why Aprea Therapeutics Inc. stock is a value investor pickEarnings Risk Report & Weekly Hot Stock Watchlists - ulpravda.ru
Why retail investors favor Aprea Therapeutics Inc. stockMarket Weekly Review & Weekly Chart Analysis and Guides - ulpravda.ru
Why Aprea Therapeutics Inc. stock is considered a top pickJuly 2025 Analyst Calls & Weekly High Conviction Ideas - ulpravda.ru
Will Aprea Therapeutics Inc. stock outperform growth indexesInsider Selling & Weekly Setup with High ROI Potential - ulpravda.ru
Can Aprea Therapeutics Inc. stock reach $100 price targetM&A Rumor & High Accuracy Trade Signal Alerts - ulpravda.ru
Will Aprea Therapeutics Inc. stock reach all time highs in 2025Sell Signal & Technical Confirmation Alerts - ulpravda.ru
Dow Theory LettersAprea Therapeutics, Inc.Common Stock (Nasdaq:APRE) Price Chart - FinancialContent
Will Aprea Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Rallies & Low Risk Growth Stock Ideas - ulpravda.ru
Why retail investors pile into Aprea Therapeutics Inc. stockJuly 2025 Institutional & High Accuracy Trade Signal Alerts - ulpravda.ru
Aprea Therapeutics, Inc.Common Stock (NQ: APRE - FinancialContent
Aprea Therapeutics files to sell 5.5M shares of common stock for holders - MSN
Aprea signals 2026 inflection as cancer trials advance and cash extends - MSN
Market Recap: Will Aprea Therapeutics Inc stock reach all time highs in 2025 - moha.gov.vn
Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in December - Defense World
Aprea Therapeutics (NASDAQ:APRE) vs. Affymax (OTCMKTS:AFFY) Financial Survey - Defense World
Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer - Quantisnow
Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE) - The Globe and Mail
Aprea Signals 2026 Inflection as Cancer Trials Advance and Cash Extends - MyChesCo
Can Aprea Therapeutics Inc. stock weather global recessionEnergy Sector Updates & Small Budget Capital Investment - bollywoodhelpline.com
Aprea Therapeutics (APRE) Stock Analysis Report | Financials & Insights - Benzinga
Will Aprea Therapeutics Inc. stock benefit from automationTrade Performance Summary & Weekly Return Optimization Alerts - Улправда
Why Aprea Therapeutics Inc. stock could rally in 20252025 Big Picture & Low Drawdown Investment Ideas - Улправда
Aprea Therapeutics (NASDAQ:APRE) Given New $5.00 Price Target at HC Wainwright - Defense World
Aprea Therapeutics reports progress in cancer drug development By Investing.com - Investing.com South Africa
HC Wainwright & Co. Maintains Aprea Therapeutics (APRE) Buy Recommendation - Nasdaq
APRE Analyst Forecasts - Quiver Quantitative
Aprea Therapeutics (APRE): HC Wainwright Maintains 'Buy' Rating, Lowers Price Target | APRE Stock News - GuruFocus
Aprea Therapeutics CEO issues letter to shareholders highlighting outlook for 2026 - marketscreener.com
Aprea Therapeutics reports progress in cancer drug development - Investing.com
Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 - The Manila Times
Aprea Therapeutics Highlights Clinical Progress and Strategic Plans in Shareholder Update Letter - Quiver Quantitative
Aprea Therapeutics Earnings Notes - Trefis
Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN
Insider Buying: John Hamill Acquires Additional Shares of Aprea Therapeutics Inc (APRE) - GuruFocus
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock By Investing.com - Investing.com South Africa
Aprea therapeutics director Duey Marc buys $25,000 in shares By Investing.com - Investing.com Canada
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock - Investing.com India
Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock By Investing.com - Investing.com South Africa
Hamill, Aprea Therapeutics CFO, buys $5,825 in stock - Investing.com
Aprea Therapeutics Director Marc Duey Acquires 21,459 Shares - TradingView — Track All Markets
Dir Duey Buys 21,459 ($25K) Of Aprea Therapeutics Inc [APRE] - TradingView — Track All Markets
Aprea Therapeutics raises $3.1 million in private placement By Investing.com - Investing.com Canada
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aprea Therapeutics Inc Stock (APRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Dec 10 '25 |
Buy |
1.17 |
5,000 |
5,825 |
27,733 |
| Gilad Oren | President/CEO |
Apr 03 '25 |
Buy |
1.84 |
5,500 |
10,110 |
345,620 |
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):